Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
Mandana Kamgar(Medical College of Wisconsin), Thomas McFall(Salk Institute for Biological Studies)
Cited by 2
Related Papers
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
|npj Precision Oncology|2022|16